## Analysis of Subjects With Specific Adverse Events (Incidence > 5 Subjects in One or More Treatment Groups) ASaT

	Placebo		Drug High Dose		Drug Low Dose	
	n	(%)	n	(%)	n	(%)
APPLICATION SITE DERMATITIS	0.0	0.0	7.0	8.86	9.0	11.69
APPLICATION SITE ERYTHEMA	0.0	0.0	15.0	18.99	12.0	15.58
APPLICATION SITE IRRITATION	0.0	0.0	9.0	11.39	9.0	11.69
APPLICATION SITE PRURITUS	6.0	8.7	22.0	27.85	22.0	28.57
APPLICATION SITE VESICLES	0.0	0.0	6.0	7.59	0.0	0.0
COUGH	0.0	0.0	0.0	0.0	6.0	7.79
DIARRHOEA	9.0	13.04	0.0	0.0	0.0	0.0
DIZZINESS	0.0	0.0	12.0	15.19	8.0	10.39
ERYTHEMA	9.0	13.04	14.0	17.72	15.0	19.48
HEADACHE	7.0	10.14	6.0	7.59	0.0	0.0
HYPERHIDROSIS	0.0	0.0	8.0	10.13	0.0	0.0
NASOPHARYNGITIS	0.0	0.0	6.0	7.59	0.0	0.0
NAUSEA	0.0	0.0	6.0	7.59	0.0	0.0
PRURITUS	8.0	11.59	26.0	32.91	23.0	29.87
RASH	0.0	0.0	11.0	13.92	13.0	16.88
SINUS BRADYCARDIA	0.0	0.0	8.0	10.13	7.0	9.09
SKIN IRRITATION	0.0	0.0	0.0	0.0	6.0	7.79
UPPER RESPIRATORY TRACT	6.0	8.7	0.0	0.0	0.0	0.0
INFECTION						
VOMITING	0.0	0.0	7.0	8.86	0.0	0.0
{\dagger}This is footnote 1\line This is footnote 2						

Source: xxx